Food Supplement Notification vs. Registration in Thailand: Which Pathway Applies

One of the first questions we get from a foreign supplement brand looking at Thailand is whether the product can simply be notified to the market the way it might be in a lighter-touch jurisdiction. It cannot. Thailand's Food Act B.E. 2522 (1979) sorts every food product into a risk tier, and MOPH Notification No. 293 B.E. 2548 (2005) places dietary supplements (ผลิตภัณฑ์เสริมอาหาร) squarely in the "standardized food" tier. That tier carries a real product approval requirement, not a notification formality, and it has to clear before a single unit is legally sold.

Why classification decides everything

Thailand's food framework runs on a tiered risk model. Products in the lower "general food" tier can reach the market without prior product approval. Dietary supplements do not live in that tier, and treating them as if they do is one of the most expensive assumptions a foreign brand can make entering this market. Under No. 293, a supplement must go through Thai FDA product approval before sale: the importer submits the product formula, ingredient specifications, and a proposed Thai-language label for review, and once Thai FDA is satisfied, it issues a food serial number (เลขสารบบอาหาร) that has to appear on every unit sold. There is no shortcut version of this process for supplements specifically, and no volume or price point exempts a product from it.

Brands coming from markets where a supplement can be sold on a simple notification basis often assume Thailand works the same way, since the products themselves look identical on the shelf. The difference is entirely in how Thai law categorizes the product, not in how the product is formulated or marketed. That gap between assumption and actual classification is where market entry timelines quietly slip by months.

This is also why we run a classification check as the first conversation with any new supplement client, before any discussion of timelines, budgets, or launch dates. A brand that assumes notification-level effort and discovers mid-project that it actually needs a full product approval file, complete with GMP evidence and a reviewed Thai label, has already lost the time it would have taken to plan for that reality from the outset. The classification question is answerable early and cheaply. It only becomes expensive when it surfaces after a launch date has already been communicated to a distributor or retail partner.

What the approval application actually requires

The application itself is filed by the Thai Orr.7 license holder, the licensed importer of record, through Thai FDA's e-Submission system. Thai FDA will not accept an incomplete package, and four categories of evidence have to be assembled before submission.

The first is the formula and specifications: the complete ingredient list, the function of each ingredient, the maximum quantity per serving, and technical specifications for every raw material used. The second is manufacturing evidence, specifically a GMP certificate from the manufacturing site demonstrating a food production system equivalent to, or not inferior to, the standard set out in MOPH No. 386 or No. 420. The third is the Thai-language label mock-up itself, which must include the product name, the mandatory category descriptor ผลิตภัณฑ์เสริมอาหาร, net quantity, full ingredient listing, importer details, expiry date, the required warning statement, and any health claims the brand intends to make. The fourth applies only when a health claim is being made: if the claim draws on MOPH No. 447 B.E. 2566 (2023), the supporting evidence for that claim has to be included in the application itself, not supplied afterward.

Each of these four elements gets reviewed together, which means a gap in one (an incomplete raw material specification, a label field that is missing, a claim without its supporting evidence) stalls the whole file rather than being processed independently.

The GMP requirement in particular catches foreign manufacturers off guard. A certificate that satisfies a home-market regulator, or even a well-recognized international standard, does not automatically satisfy Thai FDA's equivalence test against No. 386 or No. 420. The comparison has to be made explicitly, and where a gap exists, it needs to be closed, or documented and justified, before submission rather than left for Thai FDA to flag during review. The same discipline applies to the Thai-language label: a translation completed without a regulatory reviewer checking it against the required field list is a common, avoidable source of resubmission.

The line that separates a supplement from a drug

The classification question does not stop once a product clears the standardized food tier. A supplement that makes a disease claim, or that delivers a drug substance at a pharmacological dose, is not a supplement under Thai law regardless of how it is labeled or marketed. The Drug Act B.E. 2510 (1967) treats any product intended to treat, prevent, or cure a named condition as a drug, and that determination follows the product's actual formulation and intended use, not the brand's preferred positioning.

The cost of crossing that line by accident is severe. A product reclassified as a drug faces the full pharmaceutical registration pathway: typically 12 months or more, an ACTD dossier, GMP accreditation, a licensed local agent (LAR), and government fees starting at 62,000 THB. Brands that carry claims routine in their home market frequently discover those same claims cross the food-drug line the moment they reach Thailand. The vitamin and mineral ceilings under MOPH No. 448 add another version of this risk on the formulation side: a dose that exceeds the ceiling (Vitamin C above 1,000 mg per serving, for example) moves the product out of the supplement framework entirely and into drug territory, independent of any claim being made.

Neither direction of error is trivial to reverse once a product is already in the Thai market. A supplement that has been sold under a food serial number and is later found to carry drug-level claims or drug-level dosing does not simply get relabeled and continue selling. It has to come off the market while the correct registration pathway, whichever it turns out to be, runs its full course, and the brand loses whatever commercial momentum it had built in the interim. The safer sequence is always to resolve the classification question against the actual formula and the actual claim set before a single unit ships, not after a distributor has already started taking orders against a launch date.

What this means for your market entry plan

Getting the classification right before filing is the single highest-leverage step in a Thailand supplement launch. A formula and claim review against No. 293, No. 447, and No. 448 before submission catches the errors that cost nothing to fix on paper and cost months to fix once Thai FDA has already flagged them. Where a formula sits close to the food-drug boundary, the choice between adjusting the formulation, adjusting the claims, or accepting the pharmaceutical pathway needs to be made deliberately, with the actual regulatory consequences on the table, not discovered partway through a submission that is already underway. DeeMED Consulting manages this classification review and the full Thai FDA product approval process for foreign supplement brands entering the market, including food supplement registration and food serial number applications.